H.C. Wainwright Raises the PT on ​CorMedix Inc. (CRMD), Keeps a Buy

​CorMedix Inc. (NASDAQ:CRMD) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 13, H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and raised the price target from $17 to $18. The improved positive outlook follows the company’s earnings beat during its fiscal Q3 2025.

​CorMedix Inc. (NASDAQ:CRMD) released fiscal Q3 2025 results on November 12. The revenue for the quarter grew 810.21% year-over-year to $104.28 million, surpassing estimates by $18.25 million. Moreover, the EPS of $1.26 also topped the consensus by $0.63. Revenue growth was largely driven by higher-than-expected utilization of DefenCath by the company’s outpatient dialysis customers, contributing $88.8 million to the net revenue.

​Taking confidence from the results, CorMedix Inc. (NASDAQ:CRMD) raised its full-year pro forma net revenue guidance to a range of $390 to $410 million, and fourth-quarter net revenue guidance to a range of $115 to $135 million.

​Analyst Folkes noted that the robust financial results were bolstered by the recent acquisition of Melinta, which has helped the company diversify its business. Moreover, the company’s pipeline also presents significant growth catalysts, including anticipated results from the Rezzayo study and the TPN Phase 3 data for DefenCath.

​CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products to prevent and treat life-threatening infectious and inflammatory diseases.

While we acknowledge the potential of CRMD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRMD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.